How big is the cardiac resynchronisation therapy devices market?

In 2027 the market for cardiac resynchronisation therapy devices is valued at USD 4.1 Billion.

What is the anticipated CAGR of the cardiac resynchronisation therapy devices industry?

CRT Devices Market size was around USD 3.89 Billion in 2026 and is slated to grow at 6.25% CAGR from 2027 to 2036, exceeding USD 7.13 Billion by 2036.

How is the growing prevalence of cardiovascular disease shaping demand for CRT devices?

Increasing cases of heart failure and related cardiac disorders are driving adoption of CRT devices as healthcare providers expand advanced rhythm management therapies to improve heart function and long-term patient care.

Why are reimbursement policies important for the CRT devices market?

Favorable reimbursement frameworks improve patient access to cardiac resynchronization procedures, encourage broader clinical adoption, and support hospitals and cardiac centers in expanding the availability of specialized cardiac therapies.

Why do CRT-defibrillators dominate the CRT devices market?

CRT-defibrillators accounted for 79.67% of the market in 2026 because they combine cardiac resynchronization therapy with protection against life-threatening ventricular arrhythmias, supporting broad clinical adoption.

Why are CRT-pacemakers the fastest-growing product segment in the CRT devices market?

CRT-pacemakers are expanding rapidly as they provide effective cardiac resynchronization for appropriate patients without requiring defibrillation, supported by advances in pacing technology and personalized treatment approaches.

Why does North America lead the CRT devices market?

North America led in 2026, supported by advanced cardiovascular infrastructure, specialized electrophysiology services, established heart failure care pathways, and access to sophisticated cardiac therapies.

What is driving CRT device growth in Asia Pacific?

Asia Pacific is growing fastest as cardiac care infrastructure, specialized centers, healthcare expenditure, and access to advanced heart failure therapies expand.

Who are the major participants shaping the cardiac resynchronisation therapy devices landscape?

Key companies in the CRT devices market include Medtronic plc (Ireland), Abbott Laboratories (United States), Boston Scientific Corporation (United States), Biotronik SE & Co. KG (Germany), MicroPort Scientific Corporation (China), LivaNova PLC (United Kingdom), Lepu Medical Technology (China), Osypka AG (Germany)